William Blair Forecasts Immunic FY2026 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities research analysts at William Blair issued their FY2026 earnings estimates for shares of Immunic in a report issued on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.98) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

Several other brokerages have also recently weighed in on IMUX. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Immunic presently has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Price Performance

Shares of IMUX opened at $1.20 on Thursday. The business’s 50 day simple moving average is $1.07 and its 200-day simple moving average is $1.21. Immunic has a one year low of $0.92 and a one year high of $2.11. The company has a market capitalization of $108.09 million, a P/E ratio of -0.98 and a beta of 1.89.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. purchased a new stake in Immunic during the 4th quarter worth approximately $37,000. Virtu Financial LLC purchased a new stake in shares of Immunic in the third quarter valued at about $50,000. HB Wealth Management LLC acquired a new stake in shares of Immunic in the 4th quarter worth approximately $81,000. Barclays PLC acquired a new stake in Immunic during the 4th quarter valued at $84,000. Finally, Jane Street Group LLC increased its stake in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.